What is Lyprinol?

A stabilised natural marine lipid extract comprising a rare combination of lipid groups and unique Omega-3 polyunsaturated fatty acids known as PCSO-524™. Lyprinol® has been shown through clinical research to be an extremely potent anti-inflammatory.

Independent studies have shown Lyprinol® to be:

  • 100 times more potent than EPA Max
  • 125 times more potent than the original freeze dried mussel powder
  • 175 times more potent than evening primrose oil

The unique grouping of fatty acids in Lyprinol has evolved as the most potent group of Omega-3 lipids in blocking the 5 - lipoxygenase metabolic pathway responsible for inflammation in the body.
Inflammopharmacology, Vol. 0, No. 0, pp. 1-17 (1999):Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they? M.W. Whitehouse.

This unique marine product has been exposed to critical review by many research institutions world wide and is proven to have significant anti-inflammatory activity in vitro in inhibiting leukotriene synthesis and in vivo by markedly reducing the severity of adjuvant-induced poly arthritis in rat models. Various publications have been released confirming these results all of which are available on request. Leukotrienes are formed in the body via the lipoxygenase pathway and are responsible for initiating and extending the inflammatory process. The work carried out in The Queen Elizabeth Hospital and the University of Adelaide in Australia and the Charite University in Berlin, Germany has clearly demonstrated that the stabilised marine lipid Lyprinol® is a powerful modulator of the 5-lipoxygenase pathway, thus its ability to markedly reduce the damaging effects of persistent inflammation that one may find in various allergic reactions including arthritis and other inflammatory disorders including inflammation of the respiratory airways. Since many of the currently used anti-inflammatory drugs, in particular the non-steroid anti-inflammatory drugs (NSAID), function via the cyclo-oxygenase pathway, much recent international research and effort has gone into the development of modulators of the second major pathway, the lipoxygenase pathway.

There is little doubt that Lyprinol® can provide a potent means of controlling and inhibiting the damage caused by the excesses of the body's inflammatory responses. In vivo studies undertaken at The University of Queensland in Australia tested the anti-arthritic properties of Lyprinol®. Using the standard model for evaluating the potency of anti-arthritic drugs, Lyprinol® was measured against its ability to reduce the swelling which occurs in adjuvant induced poly arthritis in rats. Published in the Journal "Inflammopharmacology". The results were dramatic, with Lyprinol® reducing joint swelling by 93% compared with untreated controls. Following these outstanding findings The University of Queensland scientists set out to compare Lyprinol® with two widely used anti-arthritic drugs, namely Indomethacin & Ibuprofen. When given orally at the same dose rate (5mg/kg body wt./day) Lyprinol® outperformed the drugs Indomethacin & Ibuprofen by a factor of 2:1. This was a staggeringly successful outcome for Lyprinol®. More recently a double blind clinical trial conducted at the Hong Kong Poly Tech University has shown that the patients taking Lyprinol had greater improvement in the perception of pain as measured by the VAS, and patients’ global assessment of arthritis in those who took Lyprinol® when compared with controls from week 4 following adjustment for the change in the amount of paracetamol used between study visits. Patients who took Lyprinol® but not placebo also had improved scores in the CAIMS2-SF physical function and psychological status domains from week 4*. The results from this paper have been published in the journal ‘PROGRESS IN NUTRITION VOL. 6, N. 1, 17-31, 2004’

Lyprinol has also been trialed for the use in mild to moderate asthmatics as an adjuvant treatment. In a study conducted at the Pavlov Medical University St Petersburg, Russia there was a significant decrease in daytime wheeze, the concentration of exhaled H2O2 and an increase in morning PEF in the lipid extract group compared to the placebo group. The results of this clinical trial were published in ‘The European Respiratory Journal 2002; 20: 596–600’.

Note: Much more research has been conducted on Lyprinol over the past 25 years, all of which is available on request.

  • Third Floor, 31 C-D Wyndham St, Central, Hong Kong  
  • +61 755 991 160
  • pharma@plink.com.au

Copyright © 2017 Pharmalink International Limited. All Rights Reserved.